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1. Introduction 
Membranoproliferative glomerulonephritis (MPGN) refers to glomerular pathology in 
which there is thickening of the capillary wall together with mesangial expansion. In this 
article we firstly review the pathological features of MPGN and discuss how advances in 
our understanding of the association between abnormalities in the regulation of 
complement and MPGN have revealed limitations in the historical pathological sub-division 
of MPGN. Secondly we review the clinical presentation of MPGN, its prognosis and 
therapeutic considerations. 
2. Pathological features of MPGN 
The name ‘membranoproliferative glomerulonephritis’ derives from the light microscopic 
glomerular histologic pattern. MPGN is synonymous with ‘mesangiocapillary 
glomerulonephritis’. The glomeruli are large and hypercellular. The hypercellularity is 
typically uniform though-out the glomeruli. Mesangial hypercellularity and expansion of 
the mesangial matrix can accentuate the appearance of discrete lobules within the glomeruli. 
In some cases the hypercellularity includes infiltration of the glomerulus with neutrophils 
[1] and in severe cases monocytes have been detected in the glomerulus [2]. The degree of 
leukocyte infiltration shows some correlation with the degree of C3d deposition, possibly 
due to the chemotactic effects of complement split products. In patients who have 
undergone two biopsies, for example, when the abundance of C3d decreased in the second 
biopsy fewer leukocytes were observed [3]. The basement membranes of glomerular 
capillaries in MPGN are thickened. A characteristic change in the capillary wall is splitting 
of the glomerular basement membrane (GBM), termed ‘tram-tracking’ or ‘double-contours’. 
This is due to the inter-position of the proliferated mesangial cells between the endothelial 
cells and the GBM.  The inter-positioned mesangial cells generate new basement membrane 
material between the endothelial and mesangial cells, a process that is readily identifiable on 
electron microscopy.  
Immunofluorescence studies of glomerular immunoglobulin and C3 in MPGN typically 
demonstrated granular deposition of these immune factors along the capillary loops. 
Staining for IgG is often fainter than it is for complement C3 and is sometimes absent [4 5]. 
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An early study described three immunofluorescence patterns in MPGN: glomerular 
deposition of both immunoglobulin and C3 (66%), predominant deposition of C3 (21%) and 
deposition of C3 only (13%) [4]. The finding of immunoglobulin and complement is 
characteristic of immune complex-mediated glomerular inflammation and suggests that the 
MPGN is secondary to systemic disorders in which there is a propensity for immune-
complexes to deposit or form within the kidney. The known conditions include diseases 
such as autoimmune disorders (e.g. systemic lupus erythematosus), malignancies and 
chronic infections. Hepatitis C, for example, is now recognized as a major cause of mixed 
cryoglobulinemia and MPGN [6]. Where a systemic disorder is identifiable the MPGN is 
referred to as secondary MPGN. In the absence of a clear aetiology MPGN is appropriately 
termed ‘idiopathic or primary MPGN’.  
The finding of glomerular complement deposition alone suggests activation of the 
complement system in the absence of immunoglobulin. This most commonly is a 
consequence of activation of the complement alternative pathway. Perhaps not surprisingly 
we now know that inherited and acquired disorders of the alternative pathway are 
associated with MPGN in which the histological features are characterized by predominant 
or isolated glomerular C3 deposition. The prototypic example of this is dense deposit 
disease. In the 1960s it was recognized that ribbon-like electron dense deposits are 
detectable within the lamina densa of the glomerular basement membrane in some patients 
with glomerulonephritis [7]. These intra-membranous deposits are the histological defining 
feature of dense deposit disease and this, rather than mesangial inter-positioning, produces 
thickening of the GBM. Dense deposit disease is rare: of children whose biopsies 
demonstrate an MPGN pattern by light microscopy, less than 20% have dense deposit 
disease [8 9]. Prominent C3 deposits are virtually always present in the glomeruli of patients 
with dense deposit disease. Granular C3 deposits are almost always present within the 
mesangium, although different patterns have also been observed [8], e.g. “ring-like” pattern 
of mesangial C3 staining. Glomerular C1q and/or immunoglobulins may be seen [10]. Our 
current understanding of dense deposit disease has recently been reviewed [11].  
Since the MPGN in dense deposit disease was associated with distinct immunofluorescence 
studies (predominant or isolated glomerular C3 deposition) and GBM ultrastructural 
appearances (striking linear electron dense transformation of the lamina densa) an MPGN 
classification emerged which sub-divided MPGN initially into two groups: MPGN type I 
and MPGN type II. MPGN type I was characterized by immunoglobulin and C3 deposition 
and sub-endothelial electron dense GBM deposits [5]. MPGN type I contained both primary 
and secondary types. MPGN type II was used to describe dense deposit disease. Hence in 
the literature dense deposit disease was renamed MPGN type II. A further group, MPGN 
type III was subsequently added to describe MPGN where there were prominent 
subepithelial GBM deposits, possibly caused by immune-complexes similar to those found 
in membranous disease [12]. As in membranous disease, the deposits are associated with 
spikes along the GBM that can be detected by silver stain. A further MPGN type III variant 
was characterized by the presence of basement membrane ruptures on electron microscopy 
[13]. C3 deposition is invariably present in the glomeruli of patients with MPGN type III 
whilst immunoglobulin deposition is variable [13]. The traditional classification of MPGN is 
depicted in figure 1.  
Subsequent studies have revealed limitations in this MPGN classification. Firstly, it is now 
recognized that patients with the dense deposit disease may present with many different 
patterns of glomerular injury by light microscopy. These patterns, in addition to MPGN, 
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include mesangial proliferative and crescentic lesions [10]. In fact more than half of the 
dense deposit disease biopsies did not show MPGN. The emerging consensus is that dense 
deposit disease is a distinct pathologic entity and should not be thought of as an MPGN 
variant [10 14]. Secondly, we now know that defects in complement regulation are strongly 
associated with glomerular inflammation in which there is isolated glomerular C3 
deposition irrespective of whether the glomerular lesion is MPGN. We discuss the intimate 
association between complement and MPGN next. 
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Fig. 1. The traditional classification of MPGN. Dense deposit disease was renamed MPGN 
type II in this classification. Immunofluorescence refers to glomerular staining for 
complement C3 and IgG. GBM – glomerular basement membrane.  
3. Complement and MPGN 
The complement system is an integral component of immunity. Its principal role is 
concerned with host defence against pathogens and it forms an important component of 
innate immunity. Complement also acts as natural adjuvant enhancing the B cell response to 
antigen and more recent data implicates an important role for complement in T cell 
responses [15]. To understand the relationship between MPGN and complement it is 
important to understand how complement is activated. Binding of antibody to antigen 
forms an immune complex and immune complexes are the triggers of the complement 
classical pathway. In immune-complex associated MPGN the classical pathway is activated 
and contributes to glomerular inflammation. The complement alternative pathway is 
continuously activated i.e. requires no specific activating trigger. Unlike the classical 
pathway, the alternative pathway is antibody-independent and, through this pathway, the 
key effector molecules of the pathway (C3 and C5) can be deposited on surfaces in the 
absence of immunoglobulin. The key negative regulator of the alternative pathway is an 
abundant plasma protein called complement factor H (CFH). Early investigators studying 
MPGN hypothesized that MPGN lesions in which complement components such as C3 were 
present in the absence of immunoglobulin, were mediated by alternative pathway 
activation. We now know that both inherited and acquired causes of alternative pathway 
regulation are associated with this type of MPGN. Dense deposit disease, in which 
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glomerular C3 deposition is typically seen with little or no immunoglobulin, is associated 
with genetic and acquired factors that enhance alternative pathway activation (reviewed in 
[11]). C3 nephritic factor was associated with dense deposit disease decades ago [14] and the 
‘factor’ is now known to be an immunoglobulin which targets an enzyme complex within 
the alternative pathway. This autoantibody stabilizes the enzyme complex and enhances 
alternative pathway activation. Hence C3 nephritic factor is associated with over-activation 
of the alternative pathway. Consequently, through consumption, plasma C3 levels are 
typically low in individuals with C3 nephritic factor. Genetic factors include genetic 
deficiency of the alternative pathway regulatory protein, CFH (reviewed in [16]) and ‘gain 
of function’ mutations in the alternative pathway activation protein, complement C3 [17].   
Genetic deficiency of CFH in pigs and gene-targeted CFH-deficient mice also results in 
spontaneous MPGN [18 19]. Acquired dysregulation of the alternative pathway due to 
neutralizing autoantibodies against CFH [20] has also been described.  Recently, an 
autoantibody to factor B, an activation protein within the alternative pathway, has also been 
associated with MPGN [21]. In summary factors that increase alternative pathway activation 
have been associated with MPGN in which there is glomerular C3 with little or no 
immunoglobulin. It is clearly important to distinguish MPGN driven by these factors from 
MPGN associated with systemic immune complex disease or MPGN due to other 
aetiologies. Consequently, there has been much discussion on how to develop our current 
classification of MPGN.   
4. C3 glomerulopathy – moving away from the traditional classification of 
MPGN 
In order to identify individuals with inherited or acquired defects in complement 
regulation we proposed a classification called C3 glomerulopathy (Figure 2) [22]. C3 
glomerulopathy defines glomerular pathology characterized by isolated or predominant 
glomerular C3 deposition in the absence of immunoglobulin irrespective of both the 
glomerular light microscopic appearances and the ultrastructural appearance of the GBM 
[22]. Whilst many patients with isolated glomerular C3 deposition and complement 
abnormalities develop MPGN some do not [23 24]. For example, Servais and colleagues 
described 19 cases of primary glomerulonephritis cases with isolated deposition of C3 in 
the absence of morphological GBM changes of dense deposit disease [24]. Thirteen cases 
had an MPGN pattern by light microscopy whilst the remaining 6 did not [24]. They used 
the term ‘C3 glomerulonephritis’. Recently a familial C3 glomerulopathy associated with a 
mutation in a complement protein called complement factor H-related protein 5 (CFHR5) 
was characterised [23]. Affected individuals have renal biopsies consistent with C3 
glomerulonephritis. Biopsies show mesangial C3 deposition and variable degrees of 
mesangial hypercellularity. Mesangial and sub-endothelial GBM electron dense deposits 
are typical and some develop MPGN. These patients were identified and specifically 
investigated for complement disorders because renal biopsies demonstrated glomerular 
C3 deposition in the absence of immunoglobulin. The discovery of CFHR5 nephropathy is 
fascinating and we direct the interested reader to [25].  The impetus to propose the term 
C3 glomerulopathy was to enable the rapid identification of patients with glomerular 
disease who ought to be investigated for complement abnormalities and who may benefit 
from complement modulating therapeutic strategies. The relationship between C3 
glomerulopathy and MPGN is discussed in detail in reference [26]. 
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Fig. 2. Definition and examples of C3 glomerulopathy 
In summary the traditional MPGN classification has become outdated due to advances in 
our understanding of complement-mediated glomerular inflammation and our knowledge 
of the histopathological spectrum of dense deposit disease. Nevertheless, in reviewing 
historical studies the use of the traditional MPGN sub-groups is unavoidable. In the next 
sections we have used the traditional sub-groups acknowledging that the reader will now be 
aware of the limitations of this classification. The recent descriptions of C3 
glomerulonephritis and CFHR5 nephropathy are discussed separately.  
5. Clinical features of MPGN 
MPGN commonly presents with the nephritic syndrome (microscopic hematuria, non-
nephrotic proteinuria, and renal insufficiency). However, up to one third of the patients 
present with relatively preserved renal function and the nephrotic syndrome [27]. The 
spectrum of clinical findings is generally the same for all of the subgroups considered in this 
review, but some differences exist and are discussed under individual headings below. 
MPGN type I 
MPGN type I may be more common in children than in adults [28]. It typically presents as a 
renal limited disease, although many patients have hypertension at the time of diagnosis 
[29]. Hypertension may be less common in children [29], particularly when the disease is 
detected early through screening of asymptomatic individuals. The majority of patients 
have microscopic hematuria, and some have macroscopic haematuria [29]. Cameron 
reported that 75% of their patients with MPGN type I had normal C3 levels at the time of 
disease onset [29]. In an analysis of 9 patients with MPGN type I, however, Ooi and 
colleagues reported depressed C3 levels for all of the patients on at least one occasion [30]. 
Approximately 30% of patients have a C3 nephritic factor [29 30]. C4 levels were low for 
some of the patients.  
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MPGN type II/Dense deposit disease 
Dense deposit disease usually presents in children between the ages of 5 and 15 [14], 
although a recent series included more patients diagnosed in adulthood than in childhood 
(12). There appears to be a slight female to male preponderance [31]. The clinical 
presentation is similar to that of MPGN type I. MPGN type II usually presents with the 
nephritic syndrome [28], but proteinuria is usually present and is in the nephrotic range 
in approximately 50% of patients [31]. Interestingly, the renal disease is often preceded by 
an infection [31]. More than 80% of patients with dense deposit disease have 
hypocomplementemia at some point [29], and 100% of children with the disease had 
depressed C3 levels in the report of Nasr et al. [31]. Approximately 80% of patients with 
dense deposit disease have detectable C3 nephritic factor [32]. As described above, dense 
deposit disease is strongly associated with defects in regulation of the alternative pathway 
of complement. This underlying defect probably explains the association of dense deposit 
disease with acquired partial lipodystrophy [33] and with retinal drusen (deposits within 
Bruch’s membrane of the retina) [34]. In acquired partial lipodystrophy, uncontrolled 
complement activation causes the loss of subcutaneous fat. The drusen resemble those 
seen in patients with age related macular degeneration and presumably also form as a 
result of defective complement regulation. However, only one patient with each of these 
co-morbidities was described in a recent report of 32 patients with dense deposit disease 
[31].  
MPGN type III 
MPGN type III usually presents with similar clinical findings to those seen in MPGN type I. 
The proportion of patients with hypocomplementaemia was comparable to that of MPGN 
type I [35].  
C3 glomerulonephritis 
C3 glomerulonephritis is a recently described entity so the full spectrum of its clinical 
manifestations is not yet known. Servais et al. reported a series of 19 patients [24]. Men and 
women were represented nearly equally, and the patients ranged in age from 7 years old to 
70. Sethi et al. recently reported three more cases of C3 glomerulopathy [36], all of whom 
were adult males (aged 38-73). Approximately 30% of the patients in the two reports had a 
creatinine clearance below 60 ml/min. Most of the patients had proteinuria (eight of the 22 
patients described had nephrotic range proteinuria) and 15 patients had hematuria [24 36]. 
A comprehensive evaluation of the complement system was performed in both reports. 
Nine of the 22 total patients had depressed C3 levels.  Six patients in the first series had C3 
nephritic factor, and one of the patients reported by Sethi et al. had C3 nephritic factor. 
Mutations in complement regulatory proteins were identified in six of the patients reported 
by Servais et al. [24]. The three patients reported by Sethi et al. all carried the Tyr402His allele 
of CFH which has been identified as a risk allele for dense deposit disease [36]. 
CFHR5 nephropathy 
CFHR5 nephropathy is a familial form of C3 glomerulopathy that has to date only been 
described among individuals with Cypriot ancestry. It was characterized only recently [23 
25]. Affected individuals all carry a mutation in CFHR5 and to date only heterozygous 
affected individuals have been identified. The biological role of CFHR5 is unknown 
although there is evidence that it interacts with complement deposited within the glomeruli 
in many different glomerular pathologies [37 38]. The mutation in CFHR5 nephropathy is an 
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internal duplication in exons 2 and 3 of the CFHR5 gene. This results in a secreted 
abnormally large CFHR5 protein. The clinical course of CFHR5 nephropathy has been 
described in a comprehensive review of 91 patients from 16 pedigrees [39]. Affected patients 
have continuous microscopic haematuria and often develop macroscopic haematuria during 
periods of infection. Hypertension, proteinuria and end-stage renal failure are more 
common in men. In this report of affected individuals aged over 50 years, 80% of affected 
men developed chronic renal failure whilst 21% of affected women developed chronic renal 
failure [39]. The condition recurs in the transplanted kidney [40].   
6. Prognostic considerations in MPGN 
As highlighted in the above discussion, many of the patients who were previously identified 
simply as having MPGN are now recognized as having distinct disease processes. 
Consequently, older data regarding the prognosis of MPGN may have combined patients 
who would now be categorized differently. For example, early studies of MPGN may well 
have included patients with dense deposit disease due to defective complement regulation 
or patients with secondary MPGN caused by hepatitis C associated cryoglobulinemia.  
MPGN type I 
Studies of patients with MPGN type I have reported fairly wide variation in the long-term 
prognosis of the disease. The 10-year renal survival for children has been reported to be  
60-80% [41 42]. The patients included in these studies were treated with corticosteroids  
and other immunosuppression. The prognosis may be improved by early detection, such  
as that afforded by screening of school children [43]. This improvement could be due to  
lead-time bias, however. Adverse prognostic features include nephrotic syndrome [32 44],  
an elevated creatinine at presentation or within the first year, and structural injury on the renal 
biopsy [44]. 
MPGN type II/Dense deposit disease 
The prognosis of dense deposit disease may be worse than that for MPGN type I [8 9 29], 
although the small numbers of patients with each disease make it difficult to control for 
other variables. Spontaneous remissions of dense deposit disease are rare, and 
approximately 50% of patients will reach end-stage renal disease within 10 years [29]. Of the 
27 patients in the report by Nasr et al. for whom follow-up was known, 25.9% had a 
complete response to therapy. There was no response in the remaining patients and 25.9% 
progressed to end-stage renal disease (duration of follow-up 2 months to 24 years) [31]. Age 
and the serum creatinine at biopsy were predictive of progression to end-stage renal disease. 
Only 7.1% of the adults had a complete response to therapy. Although uncontrolled 
complement activation is believed to be pathogenic in this disease, perturbations in C3 
levels do not appear to correlate with clinical outcomes [29 31]. Recurrence in renal 
allografts is common [31 45]. 
C3 glomerulonephritis 
During the period of follow-up (ranging from 0.4 – 34 years) in the series reported by 
Servais et al. [24], most of the patients had a decline in renal function. Three patients reached 
end stage renal disease, and another two patients had creatinine clearances below 15 
mL/min. The patients described by Sethi et al. did not show a decline in renal function 
during the short period of follow-up (6 months to 3 years) [36].  
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CFHR5 nephropathy 
As mentioned above the course of this condition is more severe in males. In affected 
individuals aged over 50 years the incidence of end-stage renal failure was 78% in men and 
22% in women [39]. 
7. Therapeutic approaches to MPGN 
Given the distinct mechanisms of glomerular injury between immune-complex-mediated 
MPGN and the primary complement-mediated MPGN groups, evidence of treatment 
efficacy in one group may not be applicable to the other. However, for both groups non-
specific therapies may be beneficial at slowing the progression of renal disease. The blood 
pressure should be rigorously controlled, and ACE inhibitors or angiotensin receptor 
blockers are probably agents of choice [46]. Complications of the nephrotic syndrome, such 
as hyperlipidemia, should be treated. 
MPGN type I 
As this is a disease of immune-complex deposition, there is a rationale for treating this disease 
with immunosuppression. Unfortunately, there is not conclusive evidence that any of the 
common treatments are effective.  Perhaps the best study to date was a randomized controlled 
trial of alternate day prednisone that included 41 children with MPGN type I [47]. The patients 
had high-grade proteinuria or renal impairment, and renal survival was better in the group 
that received steroids. Although this difference did not reach significance (P = 0.07), the 
authors concluded that this was due to the small number of patients. Other uncontrolled 
studies further support the finding that long-term treatment with corticosteroids may be 
effective at inducing disease remission [9 48 49]. One of these studies included patients with 
diffuse lesions on their biopsies, but who were detected early through school-based screening 
[49]. These patients were treated with alternate day steroids, and all of the patients but one 
was treated for at least four years. Of 19 patients evaluated, four patients had persistent mild 
proteinuria but only one patient had a disease relapse (successfully treated with a second 
course of steroids). Other case series have not shown improved outcomes in patients who 
received steroids. In one such study, however, the authors determined that patients who 
received steroids were more likely to have had the nephrotic syndrome [44]. They concluded, 
therefore, that steroids may, in fact, have been beneficial. After analyzing the available data, 
Levin concluded that corticosteroids are indicated for children with nephrotic syndrome or 
with renal insufficiency [50], but the optimal criteria by which patients should be stratified for 
treatment are still under debate [44].   
Similarly, some studies have suggested a benefit of treatment with anti-platelet agents [51 
52]. A randomized, controlled trial of aspirin and dipyridamole, for example, indicated that 
treatment with these agents was effective at preserving renal function [51]. However, a long-
term follow-up study that examined renal survival in these patients from the time of 
diagnosis (not from the start of treatment) did not see a sustained benefit [53]. Another 
randomized trial of patients demonstrated that aspirin plus dipyridamole was effective at 
reducing proteinuria at 36 months [54]. The serum creatinines in both groups were 
unchanged, however, so the effect of this treatment on the progression of renal disease 
remains uncertain. 
Several case series and case reports have described patients treated with other 
immunosuppressive agents, such as cyclophosphamide or calcineurin inhibitors [29 44 55 56]. 
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The patients treated with these agents are probably selected because they have concerning 
prognostic factors. Thus, it is difficult to determine the efficacy of these agents. Case reports 
have also described patients with steroid-resistant MPGN type I who responded to 
mycophenolate mofetil [57 58]. Certainly more data is needed, but given the relative safety of 
this medication it is a reasonable choice for patients who do not respond to steroids.  
Approximately 30-60% of patients with MPGN type I who undergo renal transplantation 
have a recurrence of the disease, and disease recurrence adversely affects graft survival [59 
60]. Although there are anecdotal reports that increasing immunosuppression may be 
beneficial, there is no well established therapy for recurrent disease [60].  
MPGN type II/Dense deposit disease 
No clinical trials have been conducted in patients with dense deposit disease. Based upon 
what is known about the pathophysiology of the disease, the complement inhibitor 
eculizumab may be beneficial, and a clinical trial of this agent in dense deposit disease is 
currently underway. Eculizumab is a monoclonal antibody that blocks C5 activation and is 
currently licensed for treatment of anemia in paroxysmal nocturnal haemoglobinuria. It has 
been used successfully to treat atypical haemolytic uraemic syndrome and is likely to be 
licensed for this indication soon. 
Plasma exchange may be effective at removing autoantibodies or dysfunctional complement 
components, while also enhancing CFH function through the infusion of plasma. Plasma 
exchange was reported to be effective in two affected sisters who had a factor H mutation 
and C3 nephritic factor [61].   
The role of immunosuppressive agents in dense deposit disease is uncertain. Theoretically, 
immunosuppressive drugs may be beneficial in patients with evidence of autoantibodies, 
yet corticosteroids are not of clear benefit in this disease [14]. The patients reported by Nasr 
et al. included 18 patients who received immunosuppression [31]. The immunosuppression 
regimens included steroids in all patients. Two patients were also treated with 
mycophenolate mofetil and three received calcineurin inhibitors. A trend towards a benefit 
was seen in patients treated with immunosuppression but this did not reach significance. 
The greatest benefit was seen in those who received immunosuppression and a renin-
angiotensin system inhibitor. Recently, a patient with fulminant disease was treated with 
high-dose corticosteroids, plasma exchange, and cyclophosphamide, and apparently 
responded to treatment [62]. This patient had a low C3 level, but did not have C3 nephritic 
factor or a complement mutation, so the mechanism by which the treatment benefited the 
patient is difficult to infer.  
Based on existing data, the optimal treatment of patients with dense deposit disease is 
uncertain. A treatment algorithm incorporating complement testing and the above 
treatment options has been proposed [63]. Treatment may need to be initiated before genetic 
testing can be performed, however, and the presence or absence of C3 nephritic factor is 
probably not sufficiently accurate to guide therapy. Thus, the decision to use plasma 
exchange, standard immunosuppressive drugs, and/or eculizumab must ultimately be 
made based on the clinical severity of the disease.  
Recurrence of MPGN type II is very common in patients who receive renal transplants, and 
some estimate the recurrence rate is 100% [60]. Graft survival at 5 years is approximately 
50%, and the most common cause of graft loss is recurrent disease [64]. The impact of more 
aggressive (e.g. peri-transplant plasma exchange) or newer therapies (e.g eculizumab) 
remain unknown.  
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MPGN type III 
Patients with MPGN type III do not seem to respond as well to corticosteroids as do those 
with type I disease as assessed by disease relapse and estimated GFR [35]. Thus, other than 
non-specfic therapies there is scant evidence to guide the treatment of these patients.  
C3 glomerulonephritis 
In the series by Servais et al., five of the patients were treated with steroids [24]. The authors 
reported that there was no clear effect of treatment on the disease outcomes. The patients 
reported by Sethi et al. were treated conservatively (no patients received 
immunosuppression), and no deterioration in renal function was seen during the period of 
follow-up [36]. Thus, based upon the available data there is little evidence to support 
immunosuppression in these patients.  
CFHR5 nephropathy 
The optimum treatment for CFHR5 nephropathy presently remains unknown. There are 
theoretical grounds to investigate the utility of eculizumab in this condition e.g. during 
disease flares. The relationship between renal decline and infective episodes in CFHR5 
nephropathy implies that immunosuppressive strategies may be a potentially harmful 
approach.  
8. Conclusions 
MPGN is a fascinating glomerular pathology. We have made significant progress in 
understanding the role of complement in MPGN. There are limitations to the traditional 
histological classification. Dense deposit disease should not be referred to as MPGN type II 
since many patients with dense deposit disease do not have MPGN. C3 glomerulopathy is a 
new term which encompasses glomerular pathologies in which there is isolated or 
predominant deposition of glomerular C3. C3 glomerulopathy includes dense deposit 
disease and C3 glomerulonephritis. The most recent addition is CFHR5 nephropathy. 
Individuals with C3 glomerulopathy should be investigated for complement dysregulation 
and represent logical patient populations in which to explore the efficacy of complement 
modulating therapies.   
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